[Skip to Content]
[Skip to Content Landing]
Comment & Response
May 2016

Quality of Life of Adult Patients With Attention-Deficit/Hyperactivity Disorder Taking Methylphenidate—Reply

Author Affiliations
  • 1Medical Campus University of Oldenburg, School of Medicine and Health Sciences, Psychiatry and Psychotherapy–University Hospital, Karl-Jaspers-Klinik, Bad Zwischenahn, Germany
  • 2Department of Psychiatry and Psychotherapy, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany
  • 3Clinical Trials Unit, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany

Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Psychiatry. 2016;73(5):534-535. doi:10.1001/jamapsychiatry.2016.0051

In Reply We thank Boesen and Gøtzsche for recognizing our research efforts and for the opportunity to respond to their letter on our article.1

First and foremost, Boesen and Gøtzsche criticize the article for omitting detailed information on adverse events (AEs) and quality-of-life data. However, we believe the wealth of data this challenging landmark trial generated, if presented in detail, would require more space than is available in our presentation of the main results—the 2 × 2 design required reporting for both psychotherapeutic and medical interventions.1 Therefore, we had planned to publish separate reports on AEs and further secondary outcomes, including quality of life, and they are currently in preparation. We made this clear by stating that the secondary outcomes included those reported in JAMA Psychiatry1 and by referring readers to the publication of the study protocol.2 Although we appreciate the interest in further results, their absence from the current report is not owing to reporting bias.

First Page Preview View Large
First page PDF preview
First page PDF preview